US Stock MarketDetailed Quotes

APLS Apellis Pharmaceuticals

Watchlist
  • 37.660
  • +4.070+12.12%
Close Aug 8 16:00 ET
  • 37.660
  • 0.0000.00%
Post 17:52 ET
4.59BMarket Cap-13845P/E (TTM)

Apellis Pharmaceuticals Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Apellis Pharmaceuticals Earnings Date

Currency: USD

Period

Q2 FY2024 Earnings

Aug 1, 2024

Revenue(YoY)

199.69M

+110.26%
EPS(YoY)

-0.30

+70.59%
Analyst Rating

Strong Buy

Aug 8, 2024

Apellis Pharmaceuticals Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 16 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 220.381M--
--2024/Q3-- / 205.822M--
Aug 1, 20242024/Q2199.685M / 191.306M--
May 7, 20242024/Q1172.325M / 164.259M--
Feb 27, 20242023/Q4146.377M / 143.592M--
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 220.381M--
--2024/Q3-- / 205.822M--
Aug 1, 20242024/Q2199.685M / 191.306M--
May 7, 20242024/Q1172.325M / 164.259M--
Feb 27, 20242023/Q4146.377M / 143.592M--

Unlock Free Earnings Estimates

Apellis Pharmaceuticals Earnings Reports

  • Apellis Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

    Aug 1 07:07 ET

  • Apellis Pharmaceuticals | 10-Q: Q1 2024 Earnings Report

    May 7 07:04 ET

  • Apellis Pharmaceuticals | 10-K/A: Annual report (Amendment)

    Feb 29 17:15 ET

  • Apellis Pharmaceuticals | 10-K: FY2023 Annual Report

    Feb 27 07:05 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Aug 8, 2024

    Strong Buy

    • Buy

      81.25%

    • Hold

      18.75%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg
    Concept Gene Editing
    Gene Editing
    Intraday+0.91%